A Phase 3 interventional study of Levetiracetam in Seizures, Brain Tumors and Antiepileptics, sponsored by Tata Memorial Centre. Recruiting at 2 sites in India. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-13.
Sponsored by Tata Memorial Centre · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 52 studies testing levetiracetam in Seizures — 9 open to participants now, 9 under way, 5 of them phase 3. Levetiracetam · Seizures.
Among the 52 studies testing levetiracetam in Seizures, this one is the 5th largest by planned enrollment, is one of 2 that started in 2024, is one of 19 in phase 3, and was the 44th registered.
766 studies on the registry are indexed under Seizures; 133 are open to participants now.
Browse Seizures studies →9 of the 52 studies testing levetiracetam in Seizures are open now, in 6 countries. Recruiting first, the newest first:
Beijing Tiantan Hospital · Sites in China
Ages 18–75
Ayal A. Aizer, MD · Sites in United States
Ages 18+
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau · Sites in Spain
Ages 40+
All India Institute of Medical Sciences, Jodhpur · Sites in India
Ages 18–70
Ministry of Health and Sports, Myanmar · Sites in Burma
Ages 1 mo–12 yrs
By country, each count listing its studies:
Levetiracetam: first FDA approval 1999 (KEPPRA), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →
Of the 92 Seizures studies recruiting now, 36 (39%) set no upper age limit and 43 (47%) stop at 75 or younger; 38 take children under 18; 18 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
52 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 13 · Phase 3 20 · Phase 4 11
First in 2000; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 604 is above the median of 64 across 519 interventional studies indexed under Seizures.
Median enrollment 68 across the 52 interventional studies. Of the 37 that completed or were terminated, 22 (59%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 52 have an industry lead sponsor. The 10 most frequent:
Tata Memorial Centre is the lead sponsor of 64 studies on the registry; 42 are open to participants now.
Tata Memorial Centre has 1 study filed under Seizures — fewer than ten, so there is no comparison to draw.
2 of the studies testing levetiracetam in Seizures that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07239115Phase 3Beijing Tiantan HospitalLevetiracetam for Seizure Prevention After Brain Tumor Surgery | 2027-01 |
| NCT07072624All India Institute of Medical Sciences, JodhpurEarly Post-Traumatic Seizures Prevention Trial (E-PTS Trial) | 2027-03-15 |
Add all 2 to your calendar (.ics) → With an account.
Among the 52 studies testing levetiracetam in Seizures, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Levetiracetam is the commonly preferred anti-seizure medicine in patients with brain tumors. This drug has reduced the risk of seizure events occurring but is associated with a risk of side effects such as increased headache, drowsiness, loss of muscle coordination, and psychological challenges in patients. In patients undergoing appropriate treatment for brain tumors and controlled of seizures in the initial few months of levetiracetam, the chance of further seizures is relatively low. The optimal duration to give levetiracetam is not well defined for these patients, and currently as standard treatment levetiracetam is continued for 2-3 years. This study aims to answer this question by comparing patients on a short course of levetiracetam (experimental arm) versus a longer course of levetiracetam (standard arm), with the anticipation that a shorter duration of treatment will not lead to increased seizure episodes.
Patients with prior history of seizure from primary brain tumor in the supratentorial location with controlled seizure on levetiracetam monotherapy for at least six months will be considered for the study. Patients more than 18 years of age with KPS ≥ 50 will be eligible. Patients will be randomized in one of the two arms (standard arm or experimental arm) in a 1:1 ratio and stratified based on seizure type, location, histology, tumor grade, and adjuvant therapy. Randomization will be done by the statistician via computerized software using a permuted block design. In the standard arm, patients will continue on the same dose and schedule of levetiracetam (typically prescribed in the range of 1000-3000 mg/ day in 2-3 divided doses) for a duration of 2 years. In the experimental arm, levetiracetam will be tapered by 250- 500 mg every week and stopped. Follow-ups will be done every 3-6 months as per standard practice for the given tumor histology. Neuroimaging will be done 6-12 monthly as per routine clinical practice. The quality-of-life assessment will be done every six months. The primary endpoint is 2-year seizure free survival calculated from the time of randomization.
Patients will continue to receive standard treatment, including adjuvant therapy as standard practice. In case in either arm, the patient develops a seizure episode after stopping levetiracetam will be restarted on levetiracetam monotherapy. If a patient develops a seizure episode while on levetiracetam monotherapy, further add-on antiepileptics will be considered as per standard practice by the responsible physician. Any complications arising from previous treatments (e.g., radio necrosis) or recurrent disease during the study period will be managed according to standard institutional practice without any influence of the study.
An interim analysis is planned for harm or futility to stop the trial when quarter of the expected events have occurred (25% information time), if the observed HR is equal to or greater than the non-inferiority margin (1.47).
At the interim analysis, the one-sided P-value is calculated for testing the hypothesis HR = 1 versus the alternative HR > 1.73 (the experimental treatment is doing worse than the standard treatment). If the P-value is \<0.0110 at the interim analysis, the trial would stop with the conclusion that non-inferiority cannot be claimed.
The study will be conducted at Tata Memorial Centre and Manipal Academy of Higher Education with a total sample size of 604 patients for a duration of seven years.
Inclusion Criteria: • Age ≥ 18years
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In the standard arm, patients will continue on the same dose and schedule of levetiracetam (prescribed in the range of 1000-3000 mg/ day in 2-3 divided doses) for a duration of 2 years.
Drug: Levetiracetam
In the experimental arm, levetiracetam will be tapered by 250- 500 mg every week and then stopped.
Drug: Levetiracetam
Levetiracetam is usually preferred in brain tumor-related epilepsy. Levetiracetam is a second-generation antiepileptic drug that binds to synaptic vesicle glycoprotein SV2A, which interferes with the release of neurotransmitters from the synaptic vesicle and control seizure by multiple mechanisms.
2-year seizure free survival
Seizure-free survival measured using Kaplan-Meier product limit method survival calculated from the time of randomization.
Time frame: 7 year
Overall survival
Overall survival calculated using Kaplan-Meier product-limit method. Death from any cause will be considered as an event.
Time frame: 7 year
Progression-free survival
Progression-free survival calculated using Kaplan-Meier product-limit method. Date of radiological progression will be considered as an event.
Time frame: 7 year
Cost-benefit analysis Cost-benefit analysis
Cumulative cost of antiepileptic medications and cost of management of seizures between the two groups will be compared using proportions of expenditure.
Time frame: 7 year
Quality of life core questionnaire
The European Organization for Research and Treatment of Cancer (EORTC) quality of life (QOL) core questionnaire (C30) will be used. The summary scores will be calculated from the raw scores as per the manual, ranging from 0 to 100, with higher scores representing better outcomes. The global score and scores of subdomains will be calculated during follow-up and compared with baseline.
Time frame: 7 year
Quality of life brain cancer module
The European Organization for Research and Treatment of Cancer (EORTC) brain module (BN20) questionnaire will be used. The summary scores will be calculated from the raw scores as per the manual, ranging from 0 to 100, with higher scores representing better outcomes. The global score and scores of subdomains will be calculated during follow-up and compared with baseline.
Time frame: 7 year
Seizure-free survival between two arms using death as a competing risk
Competing risk will be analyzed using Fine and Gray using death as a competing event for seizure.
Time frame: 7 years
Started Jul 2024 (actual). Primary completion is estimated for Jun 2031, 82 months after the start.
Of 51 phase 3 interventional studies under Seizures, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 79. This study's planned 82 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Levetiracetam
Tata Memorial Centre